Skip to content
Search

Latest Stories

GASTROINTESTINAL: Treating IBS in pharmacy

By Elena Markaryan

Irritable bowel syndrome (IBS) is a common condition, affecting around one in every ten adults. It can cause unpleasant symptoms including abdominal pain, bloating and bowel symptoms. Patients can be constipated (IBS-C), or suffer diarrhoea (IBS-D), or suffer from a mix of both.


It is estimated that approximately one-third of patients with IBS experience diarrhoea as their predominant bowel habit, causing a wide range of unpleasant symptoms, which severely impact their professional and personal lives.

Linked to this, there are approximately 17 million cases of diarrhoea annually in the UK, resulting in a million GP visits which is a significant burden on the NHS. There is an unmet need to reduce duration of symptoms and numbers of GP visits and A&E attendance.

Causes and treatment

Symptoms of IBS can include abdominal pain and cramps, diarrhoea, constipation, alternating constipation and diarrhoea, changes in bowel movements, gas and bloating, food Intolerance – the most common triggers are large meals, spicy food, bread, excessive fibre – especially insoluble fibre – chocolate, alcohol, caffeine, fructose, sorbitol, fizzy drinks, fried and fatty foods.

Prof Yan Yiannakou, Professor of Neurogastroenterology at County Durham and Darlington NHS Foundation Trust, gives some useful insight into the condition: “A proportion of patients (perhaps 10 per cent) with acute infectious gastroenteritis can go on to develop chronic diarrhoea with abdominal pain. The diagnosis usually turns out to be diarrhoea predominant irritable bowel syndrome (IBS-D). It is thought that the cause of this (going from gastroenteritis to IBS-D) might be related to an activated immune system.

“The immune system in the gut becomes activated to fight the infection and should settle down after the infection has cleared. However, in some individuals this doesn’t happen and increased immune cells are present in the lining of the gut. These immune cells produce chemicals which can irritate the gut and cause diarrhoea, or might alter the balance of the bacteria which normally live in the bowel (microbiome). These bacteria are involved in producing the bowel motion and an alteration in this can make the motion too loose (or too hard).”

A bad bout of food poisoning can cause bacterial overgrowth in the small intestine leading to IBS, although the exact cause of IBS is unknown. IBS has been linked to food passing through the gut too slowly or rapidly, stress impacting on the gut, a family history of IBS, or oversensitive nerves in the gut. Some of the treatment options can include oral intestinal adsorbents and loperamide for diarrhoea, Ispaghula Husk for constipation, Hyoscine butyl bromide for cramping.

Advice for pharmacists

Those suffering with IBS can also experience acid reflux. Gastroesophageal reflux disease, or GERD, causes acid reflux, commonly referred to as heartburn and some patients can be unlucky enough to be suffering from both these conditions. Proton pump inhibitors (PPI’s) are regularly prescribed to lower stomach acid for those suffering with indigestion and heartburn and acid reflux.

Pharmacist Daniel Brash comments: “Most patients won’t be aware of the fact that PPIs (e.g. omeprazole, which is very commonly used) alter the gut flora and are associated with increased risk of infections such as gastroenteritis as a result.”

Many people with IBS suffer with chronic diarrhoea. While anti-diarrhoea medication slows down the frequency of bowel movements, the harmful substances that contribute to IBS symptoms remain in the digestive tract. To effectively alleviate the symptoms of IBS related diarrhoea, it’s useful to stock oral intestinal adsorbents, which bind bacterial toxins, immune proteins, fat molecules and bile acids which may contribute to IBS. These substances are then removed from the body with the stool, effectively alleviating symptoms of IBS flare-ups, and reducing stool frequency and duration of diarrhoea. A 20-day treatment course is recommended.

Pharmacy advice for patients

  • Try to eat at about the same time each day to help regulate bowel function.
  • Exercise regularly
  • Try to avoid your food triggers for IBS.
  • Reduce stress as much as possible, as this can be a major trigger – it’s a well-researched contributor to IBS. There’s a strong link between the brain and gut, so think about strategies to keep flare-ups under control. If you feel anxious in the mornings as your symptoms are worse, then make sure your morning routine includes plenty of time to go to the toilet.
  • Diet and lifestyle changes can go a long way to minimise IBS flare-ups, but if sufferers are finding that these changes are not working they can find themselves turning to multiple medications – which often come with unwanted side effects. Instead, pharmacists can suggest innovative, drug-free oral intestinal adsorbents that are proven to alleviate chronic diarrhoea and abdominal pain associated with IBS.

Finally, it’s worth noting that customers may be unaware that IBS is not a dangerous condition, and usually, there is no link to developing further bowel problems. However, pharmacists need to be aware of any potential ‘reg flags’ and know when to refer.

Elena Markaryan is Director of Enteromed

This article also appears in the February issue of Pharmacy Business.

More For You

Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Janet Morrison discusses pharmacy funding strategy at 2025 conference

Health Secretary Wes Streeting outlines government support for community pharmacy

CPE calls new funding deal a ‘reluctant yes’

Community Pharmacy England (CPE) was “reluctant” to accept the new pharmacy funding deal due to the significant funding gap, said the organisation’s chief executive Janet Morrison, while recognising the settlement as the first step towards stabilising the sector.

Addressing the 2025 Pharmacy Business Conference on Sunday at London Hilton Wembley, Janet shared insights into the behind-the-scenes work that led to the agreement.

Keep ReadingShow less
RPS transition to Royal College

RPS transition to Royal College: What it means for pharmacy

RPS transition to Royal College: What it means for pharmacy - Professor Claire Anderson explains

The Royal Pharmaceutical Society (RPS) is set to transition into a Royal College after securing majority support from its members in a recent ballot. However, concerns have been raised about the long-term implications of this shift.

With a voter turnout of 31.4%, 6,144 out of 19,594 eligible members participated in the vote on the Royal Charter changes. Of those, 71.1% supported the transition, well above the required two-thirds majority for a Special Resolution Vote.

Keep ReadingShow less
Pharmacies key to driving the shift from treatment to prevention

Bas Vorsteveld, Kenvue’s area managing director for Northern Europe.

Pharmacies can become frontline educators of self-care

Pharmacies have the potential to play a pivotal role in the government's transition from treatment-based healthcare to a more prevention-focused approach. However, for this shift to be successful, they require greater systemic support.

Bas Vorsteveld, Kenvue’s area managing director for Northern Europe, emphasises the importance of allowing pharmacists access to patient records to enable them to offer tailored advice and improve patient care.

Keep ReadingShow less
Community pharmacist consulting with a patient about independent prescribing.

Malcolm Harrison

Exclusive: National prescribing service 'critical' for community pharmacy, says Malcolm Harrison

A national prescribing service is “critical” for community pharmacy with all newly qualified pharmacists becoming independent prescribers from next year, according to Malcolm Harrison, chief executive of the Company Chemist Association (CCA).

“We are encouraging the NHS to work with community pharmacy to explore what that (prescribing service) could look like. There are pilots that are out there at the moment, and I know a number of pharmacies are engaged in those and exploring the different variations of what it could be,” Harrison told Pharmacy Business.

Keep ReadingShow less